<Suppliers Price>

SOR-C13

Names

[ CAS No. ]:
1187852-48-7

[ Name ]:
SOR-C13

Biological Activity

[Description]:

SOR-C13, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 has anticancer activity[1].

[Related Catalog]:

Signaling Pathways >> Membrane Transporter/Ion Channel >> Calcium Channel
Research Areas >> Cancer

[In Vivo]

SOR-C13 (i.p.; 400,600 or 800 mg/kg; daily; on days 1 to 12) can effectively inhibit the growth of tumor in female NOD/SCID mice with SKOV-3 cell[2].

[References]

[1]. S Fu , et al. Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2017 Jun;35(3):397. 

[2]. Hui Xue, et al. Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model. J Cancer. 2018 Aug 6;9(17):3196-3207. 

Chemical & Physical Properties

[ Molecular Formula ]:
C72H116N20O19

[ Molecular Weight ]:
1565.81

Related Compounds